Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC By Ogkologos - July 27, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ELEVATE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Epcoritamab Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma MOST POPULAR FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease August 17, 2021 Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated... August 4, 2021 Pattern of DNA Damage Links Colorectal Cancer and Diet High in... July 22, 2021 Ahead of a Key Meeting of EU Health Ministers, ESMO Calls... June 14, 2026 Load more HOT NEWS Coming together for Zynlonta Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination... Smoking Initiation Shifting from Teens to Young Adults ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the...
